Verekitug (UPB-101)

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company focused on developing verekitug, a first-in-class monoclonal antibody antagonist of the TSLP receptor, for major inflammatory respiratory diseases. The company has completed Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, with an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Its strategy is predicated on disrupting a key upstream inflammatory mediator to potentially achieve broader efficacy and a more convenient dosing regimen than existing biologics, aiming to capture significant share in large, underserved markets.

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company focused on developing verekitug, a first-in-class monoclonal antibody antagonist of the TSLP receptor, for major inflammatory respiratory diseases. The company has completed Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, with an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Its strategy is predicated on disrupting a key upstream inflammatory mediator to potentially achieve broader efficacy and a more convenient dosing regimen than existing biologics, aiming to capture significant share in large, underserved markets.

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company focused on developing verekitug, a first-in-class monoclonal antibody antagonist of the TSLP receptor, for major inflammatory respiratory diseases. The company has completed Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, with an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Its strategy is predicated on disrupting a key upstream inflammatory mediator to potentially achieve broader efficacy and a more convenient dosing regimen than existing biologics, aiming to capture significant share in large, underserved markets.

Therapeutic Areas